The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
Abstract
PURPOSE: The American Urological Association Prostate Guideline Update Panel was charged with updating the Guidelines for Clinically Localized Prostate Cancer. In assessing outcomes with treatment, it became apparent that a highly variable number of definitions exist with respect to biochemical recurrence. Herein, we review the variability in published definitions of biochemical recurrence and make recommendations directed toward improving this terminology by recommending a standard definition in patients treated with radical prostatectomy. MATERIALS AND METHODS: Four PubMed literature searches were performed between May 2001 and April, 2004 and covered articles published from 1991 through early 2004. The search terms included the MeSH major headings of prostate cancer and prostatic neoplasm. All potentially relevant articles were retrieved and a more detailed screen for relevance was performed. An article was considered relevant if it reported treatment outcomes of patients with clinical T1 or T2N0M0 prostate cancer. Data extractors recorded the definition of biochemical recurrence and definitions were then collapsed into categories representing the same criteria. The results of biochemical failure were subcategorized by initial treatment. RESULTS: Of 13,800 citations, a total of 436 articles were selected. Among these, a total of 145 articles contained 53 different definitions of biochemical recurrence for those treated with radical prostatectomy. Of these, the most common definition (35) was a prostate specific antigen of >0.2 ng/mL or a slight variation thereof. In addition, a total of 208 articles reported 99 different definitions of biochemical failure among those treated with radiation therapy. Of these, the American Society for Therapeutic Radiology and Oncology definition (70) and/or a variation thereof was the most commonly reported. In total, 166 different definitions of biochemical failure were identified. Following radical prostatectomy, the Panel recommends defining biochemical recurrence as an initial serum prostate specific antigen of > or =0.2 ng/mL, with a second confirmatory level of prostate specific antigen of >0.2 ng/mL. The Panel recommends the use of the American Society for Therapeutic Radiology and Oncology criteria for patients treated with radiation therapy and acknowledges that these criteria will soon be updated although not yet published. CONCLUSIONS: A high degree of variability in the definition of biochemical recurrence exists following treatment for localized prostate cancer. Strict definitions for biochemical recurrence are necessary to identify men at risk for disease progression and to allow meaningful comparisons among patients treated similarly. The Panel acknowledges the American Society for Therapeutic Radiology and Oncology criteria and future modifications thereof for those receiving radiation therapy and recommends the newly developed American Urological Association criteria for those treated with radical prostatectomy. The purpose for the establishment of this standard is for data reporting purposes and for comparison of similarly treated patients. It is not intended to represent a threshold value for which to initiate treatment. The Panel acknowledges that the clinical decision to initiate treatment will be dependent on multiple factors including patient and physician interaction rather than a specific prostate specific antigen threshold value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P., & Barrett, D. M. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32399-6 · Cited by 672
Kupelian, P. A., Potters, L., Khuntia, D., Ciezki, J. P., Reddy, C. A., Reuther, A. M., Carlson, T. P., & Klein, E. A. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00784-3 · Cited by 457
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66452-x · Cited by 408
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Cote, K., Loffredo, M., Schultz, D., Chen, M., Tomaszewski, J. E., Renshaw, A. A., Wein, A., et al. (2002) · Cancer · doi:10.1002/cncr.10657 · Cited by 356
Self-citationPROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER
MOUL, J. W. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67511-8 · Cited by 350
Self-citationAMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · The Journal of Urology · doi:10.1097/00005392-200104000-00020 · Cited by 348
Middleton, R. G., Thompson, I. M., Austenfeld, M. S., Cooner, W. H., Correa, R. J., Gibbons, R. P., Miller, H. C., Oesterling, J. E., Resnick, M. I., & Smalley, S. R. (1995) · PubMed · Cited by 261
Self-citationMiddleton, R. G., Thompson, I. M., Austenfeld, M. S., Cooner, W. H., Correa, R. J., Gibbons, R. P., Miller, H. C., Oesterling, J. E., Resnick, M. I., Smalley, S. R., et al. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)66718-1 · Cited by 214
Self-citation
Cited by
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Self-citationThompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Self-citationGuideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.003 · Cited by 1,113
Self-citationBolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J.-F., van Velthoven, R., Colombel, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61253-7 · Cited by 867
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Cooperberg, M. R., Hilton, J. F., & Carroll, P. R. (2011) · Cancer · doi:10.1002/cncr.26169 · Cited by 457
Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709802104 · Cited by 401
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Calais, J., Ceci, F., Cho, S. Y., Fanti, S., Giesel, F. L., Goffin, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06089-w · Cited by 410
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D., Wong, J. Y. C., Pantel, A. R., Cho, S. Y., Gage, K. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4573 · Cited by 389
Li, T., Su, Y., Mei, Y., Leng, Q., Leng, B., Liu, Z., Stass, S. A., & Jiang, F. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.127 · Cited by 362
Cooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
Molecular imaging in oncology: Current impact and future directions
Rowe, S. P., & Pomper, M. G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21713 · Cited by 337
Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp122 · Cited by 336
Giesel, F. L., Knorr, K., Spohn, F., Will, L., Maurer, T., Flechsig, P., Neels, O., Schiller, K., Amaral, H., Weber, W. A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.212233 · Cited by 334
Sargos, P., Chabaud, S., Latorzeff, I., Magné, N., Benyoucef, A., Supiot, S., Pasquier, D., Abdiche, M. S., Gilliot, O., Graff-Cailleaud, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30454-x · Cited by 329
Cooperberg, M. R., Vickers, A. J., Broering, J. M., Carroll, P. R., & for the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators (2010) · Cancer · doi:10.1002/cncr.25456 · Cited by 311
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
Duffy, M. J. (2013) · Medical Principles and Practice · doi:10.1159/000338393 · Cited by 278
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy
Pastuszak, A. W., Pearlman, A. M., Lai, W. S., Godoy, G., Sathyamoorthy, K., Liu, J. S., Miles, B. J., Lipshultz, L. I., & Khera, M. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.02.002 · Cited by 183
Yanai, Y., Kosaka, T., Mikami, S., Hongo, H., Yasumizu, Y., Takeda, T., Matsumoto, K., Miyauchi, J., Kitano, S., & Oya, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-01900-4 · Cited by 28
Metadata
- Authors
- Cookson, M. S., Aus, G., Burnett, A. L., Canby-Hagino, E. D., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernandez, J., Higano, C. S., Kraus, S. R., Moul, J. W., Tangen, C., Thrasher, J. B., & Thompson, I.
- Venue
- Journal of Urology
- Published
- 2007-02
- Volume
- 177
- Issue
- 2
- Pages
- 540-545
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2053198390
- Cited by
- 844
- References
- 16
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.